Synlogic receives rare pediatric disease designation from fda for synb1934 for phenylketonuria (pku)

Cambridge, mass., jan. 19, 2023 (globe newswire) -- synlogic, inc. (nasdaq: sybx), the leading company advancing therapeutics based on synthetic biology, today announced that synb1934 was granted rare pediatric disease designation (rpdd) by the u.s. food and drug administration (fda) for the potential treatment of phenylketonuria (pku).
SYBX Ratings Summary
SYBX Quant Ranking